GlassScriptPhysician profile
James K Lisowski
NPI 1568909042
$2,096.59
in general payments reported to CMS, 2019-2025
17 companies · $239 in 2025
The $239 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $14.29 · 2022: $19.59 · 2023: $1,017 · 2024: $806 · 2025: $239.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,063.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,062.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $418.36 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $404.35 | 2023-2024 | Xarelto |
| Pfizer INC. | $221.41 | 2023-2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $197.34 | 2023-2025 | Lifevest |
| Merck Sharp & Dohme LLC | $187.14 | 2023-2025 | Zerbaxa, Dificid, Verquvo |
| Novartis Pharmaceuticals Corporation | $117.69 | 2023-2024 | |
| Paratek Pharmaceuticals, INC. | $94.44 | 2023-2025 | Nuzyra |
| Gilead Sciences, INC. | $83.08 | 2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $72.06 | 2024 | Xifaxan |
| Novo Nordisk INC | $65.50 | 2023-2024 | Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $64.28 | 2023 | Farxiga, Lokelma |
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.43 | 2025 | Jardiance |
| Kestra Medical Technology Services, INC. | $37.59 | 2023 | Assure Wcd |
| Daiichi Sankyo INC. | $36.21 | 2023 | Injectafer |
| Inari Medical, INC. | $18.78 | 2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $16.64 | 2024 | Trelegy Ellipta, Arexvy |
| E.R. Squibb & Sons, L.L.C. | $14.29 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Lisowski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.